CN108367006B - 用于治疗血液癌症的赛度替尼 - Google Patents

用于治疗血液癌症的赛度替尼 Download PDF

Info

Publication number
CN108367006B
CN108367006B CN201680073276.XA CN201680073276A CN108367006B CN 108367006 B CN108367006 B CN 108367006B CN 201680073276 A CN201680073276 A CN 201680073276A CN 108367006 B CN108367006 B CN 108367006B
Authority
CN
China
Prior art keywords
cerdulatinib
patient
pharmaceutically acceptable
lymphoma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680073276.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN108367006A (zh
Inventor
格雷戈里·科菲
冯佳佳
安德鲁·斯蒂尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portola Pharmaceuticals LLC
Original Assignee
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC
Publication of CN108367006A publication Critical patent/CN108367006A/zh
Application granted granted Critical
Publication of CN108367006B publication Critical patent/CN108367006B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680073276.XA 2015-12-04 2016-12-02 用于治疗血液癌症的赛度替尼 Active CN108367006B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562263582P 2015-12-04 2015-12-04
US62/263,582 2015-12-04
US201662342727P 2016-05-27 2016-05-27
US201662342755P 2016-05-27 2016-05-27
US62/342,727 2016-05-27
US62/342,755 2016-05-27
US201662371145P 2016-08-04 2016-08-04
US62/371,145 2016-08-04
PCT/US2016/064824 WO2017096303A2 (en) 2015-12-04 2016-12-02 Cerdulatinib for treating hematological cancers

Publications (2)

Publication Number Publication Date
CN108367006A CN108367006A (zh) 2018-08-03
CN108367006B true CN108367006B (zh) 2021-12-31

Family

ID=57614468

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680073276.XA Active CN108367006B (zh) 2015-12-04 2016-12-02 用于治疗血液癌症的赛度替尼

Country Status (8)

Country Link
US (2) US10736895B2 (enExample)
EP (1) EP3383396B1 (enExample)
JP (1) JP6944936B2 (enExample)
CN (1) CN108367006B (enExample)
AU (1) AU2016363005A1 (enExample)
CA (1) CA2950640A1 (enExample)
ES (1) ES2959692T3 (enExample)
WO (1) WO2017096303A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3302485B1 (en) * 2015-05-29 2023-07-12 Alexion Pharmaceuticals, Inc. Cerdulatinib for the treatment of b-cell malignancies
US20170042896A1 (en) 2015-08-12 2017-02-16 Portola Pharmaceuticals, Inc. Cerdulatinib for treating myeloma
WO2019138291A2 (en) * 2018-01-09 2019-07-18 Dermavant Sciences GmbH Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof
CN112074271B (zh) * 2018-05-04 2023-10-20 博尔托拉制药公司 用于治疗淋巴瘤的方法
JP7324778B2 (ja) 2018-05-04 2023-08-10 ポートラ ファーマシューティカルズ， エルエルシー セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態
TWI805751B (zh) 2018-05-04 2023-06-21 美商普托拉製藥有限公司 賽度替尼(cerdulatinib)之合成
WO2020165861A1 (en) * 2019-02-15 2020-08-20 Janssen Biotech, Inc. Combination therapy for treatment of b-cell malignancies
US20230181581A1 (en) * 2020-05-26 2023-06-15 Alexion Pharmaceuticals, Inc. Circulating b cell subpopulations in indolent b cell lymphoma

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999031073A1 (en) 1997-12-15 1999-06-24 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CN1665789A (zh) 2002-06-28 2005-09-07 山之内制药株式会社 二氨基嘧啶酰胺衍生物
WO2008009458A1 (en) 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
PT2201840E (pt) 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
CA2960692C (en) 2008-04-16 2019-09-24 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8367689B2 (en) 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
BR122019016429B1 (pt) 2009-05-26 2020-03-24 Abbvie Ireland Unlimited Company Compostos inibidores da atividade de proteínas bcl-2 antiapoptótica e composição farmacêutica compreendendo ditos compostos
CA2780759A1 (en) 2009-12-01 2011-06-09 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
US9357229B2 (en) 2010-07-28 2016-05-31 Qualcomm Incorporated Coding motion vectors in video coding
WO2012045010A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combinations of 4-(3-(2h-1,2,3-triazo-2-yl) phenylamino)-2-((1r,2s)-2-aminocyclohexylamino) pyrimidine-5-carboxamide and fludarabine
AU2011332043C1 (en) 2010-11-23 2016-11-10 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
HK1198579A1 (en) 2011-08-10 2015-04-30 Novartis Pharma Ag Jak p13k/mtor combination therapy
WO2014018567A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
CA2890111A1 (en) 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
EP3302485B1 (en) 2015-05-29 2023-07-12 Alexion Pharmaceuticals, Inc. Cerdulatinib for the treatment of b-cell malignancies
US20170042896A1 (en) 2015-08-12 2017-02-16 Portola Pharmaceuticals, Inc. Cerdulatinib for treating myeloma
JP7324778B2 (ja) 2018-05-04 2023-08-10 ポートラ ファーマシューティカルズ， エルエルシー セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A Phase I Open-Label，Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies;PATEL MANISH ET AL;《BLOOD》;20141231;摘要 *
BLUNT MATTHEW D ET AL.The Syk\Jak Inhibitor Cerdulatinib(PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling.《BLOOD》.2015,摘要. *
Cerdulatinib，a novel dual SYK/JAK kinase inhibitor，has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma;MA JIAO ET AL:;《ONCOTARGET》;20140609;摘要，讨论 *
The Syk\Jak Inhibitor Cerdulatinib(PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling;BLUNT MATTHEW D ET AL;《BLOOD》;20151203;摘要 *

Also Published As

Publication number Publication date
US20210000827A1 (en) 2021-01-07
ES2959692T3 (es) 2024-02-27
WO2017096303A3 (en) 2017-08-03
US11446300B2 (en) 2022-09-20
JP2018535996A (ja) 2018-12-06
EP3383396A2 (en) 2018-10-10
AU2016363005A1 (en) 2018-07-05
US10736895B2 (en) 2020-08-11
CN108367006A (zh) 2018-08-03
EP3383396B1 (en) 2023-07-12
JP6944936B2 (ja) 2021-10-06
CA2950640A1 (en) 2017-06-04
US20180353506A1 (en) 2018-12-13
WO2017096303A2 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
CN108367006B (zh) 用于治疗血液癌症的赛度替尼
JP7323592B2 (ja) 癌を治療するための併用療法
US12350269B2 (en) Cerdulatinib for the treatment of b-cell malignancies
US9259399B2 (en) Targeting CDK4 and CDK6 in cancer therapy
KR102849513B1 (ko) 암 치료 방법
CN106659716A (zh) 阿吡莫德组合物及其使用方法
CN114828842A (zh) 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物
HK1262118A1 (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK1262118B (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
Pilehvari et al. The Role of Genetics and Synergistic Effect of Targeting Common Genetic Mutations in Acute Lymphoblastic Leukemia (ALL)
HK40061501A (en) Combination therapy for treating cancer
HK1253804B (en) Cerdulatinib for the treatment of b-cell malignancies
HK1253804A1 (en) Cerdulatinib for the treatment of b-cell malignancies
Puvvada et al. Emerging Frontiers in Therapeutics of Diffuse Large B Cell Lymphoma: Epigenetics and B Cell Receptor Signaling
HK1229709B (en) Combination therapy for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant